Treating breast cancer with cell-based approaches: an overview

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–E386.
   PubMed Web of Science ®Google Scholar
• DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1495-1506.
   PubMed Web of Science ®Google Scholar
• Cardoso F, Costa A, Senkus E, et al. 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol. 2017. Published online as 10.1093/annonc/mdx036
   Web of Science ®Google Scholar
• Montemurro F, Ueno NT, Rondon G, et al. High-dose chemotherapy with hematopoietic stem-cell transplantation for breast cancer: current status, future trends. Clin Breast Cancer. 2000;1(3):197–209.
   PubMedGoogle Scholar
• Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–2205.
   PubMed Web of Science ®Google Scholar
• Kessinger A, Armitage JO, Landmark JD, et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood. 1988;71(3):723–727.
   PubMed Web of Science ®Google Scholar
• Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13(10):2483–2489.
   PubMed Web of Science ®Google Scholar
• Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol. 2001;19(11):2771–2777.
   PubMed Web of Science ®Google Scholar
• Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet. 2000;355(9208):999–1003.
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, O’Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med. 2000;342(15):1069–1076.
   PubMed Web of Science ®Google Scholar
• Schmid P, Schippinger W, Nitsch T, et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol. 2005;23(3):432–440.
   PubMed Web of Science ®Google Scholar
• Lotz JP, Cure H, Janvier M, et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer. 2005;41(1):71–80.
   PubMed Web of Science ®Google Scholar
• Biron P, Durand M, Roche H, et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant. 2008;41(6):555–562.
   PubMed Web of Science ®Google Scholar
• Crump M, Gluck S, Tu D, et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol. 2008;26(1):37–43.
   PubMed Web of Science ®Google Scholar
• Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol. 2005;23(10):2191–2200.
   PubMed Web of Science ®Google Scholar
• Leonard RC, Lind M, Twelves C, et al. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst. 2004;96(14):1076–1083.
   PubMedGoogle Scholar
• Basser RL, O’Neill A, Martinelli G, et al. Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol. 2006;24(3):370–378.
   PubMed Web of Science ®Google Scholar
• Wilking N, Lidbrink E, Wiklund T, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol. 2007;18(4):694–700.
   PubMed Web of Science ®Google Scholar
• Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366(9501):1935–1944.
   PubMed Web of Science ®Google Scholar
• Coombes RC, Howell A, Emson M, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol. 2005;16(5):726–734.
   PubMed Web of Science ®Google Scholar
• Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349(1):17–26.
   PubMed Web of Science ®Google Scholar
• Farquhar C, Marjoribanks J, Basser R, et al. High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with metastatic breast cancer. Cochrane Database Syst Rev. 2005;3:CD003142.
   Google Scholar
• Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. J Clin Oncol. 2011;29(24):3214–3223.
   PubMed Web of Science ®Google Scholar
• Berry DA, Ueno NT, Johnson MM, et al. High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials. J Clin Oncol. 2011;29(24):3224–3231.
   PubMed Web of Science ®Google Scholar
• Farquhar C, Marjoribanks J, Lethaby A, et al. High-dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy for women with early poor prognosis breast cancer. Cochrane Database Syst Rev. 2016;5:CD003139.
   Google Scholar
• Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–752.
   PubMed Web of Science ®Google Scholar
• Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100(14):8418–8423.
   PubMed Web of Science ®Google Scholar
• Mustacchi G, Biganzoli L, Pronzato P, et al. HER2-positive metastatic breast cancer: a changing scenario. Crit Rev Oncol Hematol. 2015;95(1):78–87.
   PubMed Web of Science ®Google Scholar
• Carey L, Winer E, Viale G, et al. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7(12):683–692.
   PubMed Web of Science ®Google Scholar
• Pedrazzoli P, Martino M, Delfanti S, et al. High-dose chemotherapy with autologous hematopoietic stem cell transplantation for high-risk primary breast cancer. J Natl Cancer Inst Monogr. 2015;2015(51):70–75.
   PubMedGoogle Scholar
• Thomas ED, Flournoy E, Buckner CD, et al. Cure of leukemia by marrow transplantation. Leuk Res. 1977;1(1):67–70.
   Web of Science ®Google Scholar
• Thomas ED, Buckner CD, Banaji M, et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood. 1977;49(4):511–533.
   PubMed Web of Science ®Google Scholar
• Weiden PL, Flournoy N, Thomas ED, et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med. 1979;300(19):1068–1073.
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood. 1995;86(5):2041–2050.
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos EB, Carabasi MH, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood. 1995;86(4):1261–1268.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–1321.
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med. 2000;343(11):750–758.
   PubMed Web of Science ®Google Scholar
• Carvallo C, Childs R. Nonmyeloablative stem cell transplantation as immunotherapy for kidney cancer and other metastatic solid tumors. Cytotechnology. 2003;41(2–3):197–206.
   PubMed Web of Science ®Google Scholar
• Carnevale-Schianca F, Cignetti A, Capaldi A, et al. Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood. 2006;107(9):3795–3803.
   PubMed Web of Science ®Google Scholar
• Eibl B, Schwaighofer H, Nachbaur D, et al. Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood. 1996;88(4):1501–1508.
   PubMed Web of Science ®Google Scholar
• Ben-Yosef R, Or R, Nagler A, et al. Graft-versus-tumour and graft-versus-leukaemia effect in patient with concurrent breast cancer and acute myelocytic leukaemia. Lancet. 1996;348(9036):1242–1243.
   PubMed Web of Science ®Google Scholar
• Ueno NT, Rondon G, Mirza NQ, et al. Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol. 1998;16(3):986–993.
   PubMed Web of Science ®Google Scholar
• Ueno NT, Rizzo JD, Demirer T, et al. Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant. 2008;41(6):537–545.
   PubMed Web of Science ®Google Scholar
• Bregni M, Dodero A, Peccatori J, et al. Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood. 2002;99(11):4234–4236.
   PubMed Web of Science ®Google Scholar
• Bishop MR, Fowler DH, Marchigiani D, et al. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol. 2004;22(19):3886–3892.
   PubMed Web of Science ®Google Scholar
• Carella AM, Beltrami G, Corsetti MT, et al. Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet. 2005;366(9482):318–320.
   PubMed Web of Science ®Google Scholar
• de Souza JA, Davis ML, Rondon G, et al. Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. Bone Marrow Transplant. 2009;44(2):81–87.
   PubMed Web of Science ®Google Scholar
• McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97(11):3390–3400.
   PubMed Web of Science ®Google Scholar
• Demirer T, Barkholt L, Blaise D, et al. Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nat Clin Pract Oncol. 2008;5(5):256–267.
   PubMedGoogle Scholar
• Disis ML, Stanton SE. Immunotherapy in breast cancer: an introduction. Breast. 2017. [Epub ahead of print]. Doi:10.1016/j.breast.2017.01.013
   PubMedGoogle Scholar
• Brossart P, Heinrich KS, Stuhler G, et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood. 1999;93(12):4309–4317.
   PubMed Web of Science ®Google Scholar
• Fremd C, Stefanovic S, Beckhove P, et al. Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients. Oncoimmunology. 2016;5(1):e1057387.
   PubMed Web of Science ®Google Scholar
• Goodell V, Waisman J, Salazar LG, et al. Level of HER-2/neu protein expression in breast cancer may affect the development of endogenous HER-2/neu-specific immunity. Mol Cancer Ther. 2008;7(3):449–454.
   PubMed Web of Science ®Google Scholar
• Feuerer M, Rocha M, Bai L, et al. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer. 2001;92(1):96–105.
   PubMed Web of Science ®Google Scholar
• Tabuchi Y, Shimoda M, Kagara N, et al. Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer. Breast Cancer Res Treat. 2016;157(1):55–63.
   PubMed Web of Science ®Google Scholar
• Montgomery RB, Makary E, Schiffman K, et al. Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase. Cancer Res. 2005;65(2):650–656.
   PubMed Web of Science ®Google Scholar
• Disis ML, Knutson KL, Schiffman K, et al. Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat. 2000;62(3):245–252.
   PubMed Web of Science ®Google Scholar
• Katayama H, Boldt C, Ladd JJ, et al. An autoimmune response signature associated with the development of triple-negative breast cancer reflects disease pathogenesis. Cancer Res. 2015;75(16):3246–3254.
   PubMed Web of Science ®Google Scholar
• Ladd JJ, Chao T, Johnson MM, et al. Autoantibody signatures involving glycolysis and splicesome proteins precede a diagnosis of breast cancer among postmenopausal women. Cancer Res. 2013;73(5):1502–1513.
   PubMed Web of Science ®Google Scholar
• Denkert C, von Minckwitz G, Darb-Esfahani S, et al. Abstract S1-09: evaluation of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarker in different subtypes of breast cancer treated with neoadjuvant therapy - A metaanalysis of 3771 patients. Cancer Res. 2017;77(4Supplement):S1-09-S1.
   Google Scholar
• Luen SJ, Salgado R, Fox S, et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol. 2017;18(1):52–62.
   PubMed Web of Science ®Google Scholar
• Hendrickx W, Simeone I, Anjum S, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology. 2017;6(2):e1253654.
   PubMed Web of Science ®Google Scholar
• Travis Clifton G, Litton JK, Arrington K, et al. Results of a phase Ib trial of combination immunotherapy with a CD8+ T cell eliciting vaccine and trastuzumab in breast cancer patients. Ann Surg Oncol. 2017;24(8):2161-2167.
   PubMed Web of Science ®Google Scholar
• Clifton GT, Peoples GE, Mittendorf EA. The development and use of the E75 (HER2 369-377) peptide vaccine. Future Oncol. 2016;12(11):1321–1329.
   PubMed Web of Science ®Google Scholar
• Gates JD, Clifton GT, Benavides LC, et al. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010;28(47):7476–7482.
   PubMed Web of Science ®Google Scholar
• Milani A, Sangiolo D, Montemurro F, et al. Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol. 2013;24(7):1740–1748.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460–2467.
   PubMed Web of Science ®Google Scholar
• Nanda R, Specht J, Dees C, et al. Abstract P6-10-03: KEYNOTE-012: long-lasting responses in a phase Ib study of pembrolizumab for metastatic triple-negative breast cancer (mTNBC). Cancer Res. 2017;77(4Supplement):P6-10-03-P6-10-03.
   Google Scholar
• Emens LA, Braiteh FS, Cassier P, et al. Abstract 2859: inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC). Cancer Res. 2015;75(15 Supplement):2859.
   Web of Science ®Google Scholar
• Rugo H, Delord J-P, Im S-A, et al. Abstract S5-07: preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028. Cancer Res. 2016;76(4 Supplement):S5-07-S5.
   Web of Science ®Google Scholar
• Dirix L, Takacs I, Nikolinakos P, et al. Abstract S1-04: avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase Ib JAVELIN solid tumor trial. Cancer Res. 2016;76(4 Supplement):S1-04-S1.
   Web of Science ®Google Scholar
• Adams S, Robinson Diamond J, Paige Hamilton E, et al. Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol. 2016;34(Suppl15): abstr. 1009.
   Google Scholar
• Emens LA. Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther. 2012;12(12):1597–1611.
   PubMed Web of Science ®Google Scholar
• Santa-Maria CA, Park SJ, Jain S, et al. Breast cancer and immunology: biomarker and therapeutic developments. Expert Rev Anticancer Ther. 2015;15(10):1215–1222.
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25(3):243–251.
   PubMed Web of Science ®Google Scholar
• Feuerer M, Beckhove P, Bai L, et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med. 2001;7(4):452–458.
   PubMed Web of Science ®Google Scholar
• Domschke C, Ge Y, Bernhardt I, et al. Long-term survival after adoptive bone marrow T cell therapy of advanced metastasized breast cancer: follow-up analysis of a clinical pilot trial. Cancer Immunol Immunother. 2013;62(6):1053–1060.
   PubMed Web of Science ®Google Scholar
• Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004;114(1):67–76.
   PubMed Web of Science ®Google Scholar
• Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer. 2011;2:363–368.
   PubMed Web of Science ®Google Scholar
• Wang ZX, Cao JX, Wang M, et al. Adoptive cellular immunotherapy for the treatment of patients with breast cancer: a meta-analysis. Cytotherapy. 2014;16(7):934–945.
   PubMed Web of Science ®Google Scholar
• Yu S, Li A, Liu Q, et al. Chimeric antigen receptor T cells: a novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78.
   PubMed Web of Science ®Google Scholar
• Hillerdal V, Nilsson B, Carlsson B, et al. T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells. Proc Natl Acad Sci U S A. 2012;109(39):15877–15881.
   PubMed Web of Science ®Google Scholar
• Fesnak AD, June CH, Levine BL. Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016;16(9):566–581.
   PubMed Web of Science ®Google Scholar
• Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507–1517.
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509–1518.
   PubMed Web of Science ®Google Scholar
• Kochenderfer JN, Dudley ME, Kassim SH, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540–549.
   PubMed Web of Science ®Google Scholar
• Chong EA, Svoboda J, Nasta SD, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy. Blood. 2016;128(22):1100.
   Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725–733.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–851.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Brawley VS, Hegde M, et al. Human epidermal growth factor receptor 2 (HER2) -specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688–1696.
   PubMed Web of Science ®Google Scholar
• Massari F, Santoni M, Ciccarese C, et al. The immunocheckpoints in modern oncology: the next 15 years. Expert Opin Biol Ther. 2015;15(7):917–921.
   PubMed Web of Science ®Google Scholar
• John LB, Devaud C, Duong CP, et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res. 2013;19(20):5636–5646.
   PubMed Web of Science ®Google Scholar
• Peng W, Liu C, Xu C, et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines. Cancer Res. 2012;72(20):5209–5218.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Henderson MA, Giuffrida L, et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J Clin Invest. 2017;127(3):929–941.
   PubMed Web of Science ®Google Scholar
• Chong EA, Melenhorst JJ, Lacey SF, et al. PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR. Blood. 2017;129(8):1039–1041.
   PubMed Web of Science ®Google Scholar
• Loibl S, Gianni L. HER2-positive breast cancer. Lancet. 2017;389(10087):2415–2429.
   PubMed Web of Science ®Google Scholar
• Turner NC, Neven P, Loibl S, et al. Advances in the treatment of advanced oestrogen-receptor-positive breast cancer. Lancet. 2017;389(10087):2403–2414.
   PubMed Web of Science ®Google Scholar
• Denkert C, Liedtke C, Tutt A, et al. Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2017;389(10087):2430–2442.
   PubMed Web of Science ®Google Scholar
• Stronen E, Toebes M, Kelderman S, et al. Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337–1341.
   PubMed Web of Science ®Google Scholar